Trial Profile

A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 May 2019 This trial has been completed in UK as per European Clinical Trials Database record
14 Nov 2018 Results assessing the effectiveness and cost of fulvestrant versus anastrozole from FIRST and FALCON trials, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
09 Dec 2017 Results of FALCON, FIRST and CONFIRM studies comparing treatment effect of Fulvestrant vs comparators in post-menopausal patients, presented at the 40th Annual San Antonio Breast Cancer Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com